Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2763264 | 0.88 | MEN1 (0.43) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL2762910 | 0.85 | KCNH2 (0.45) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL2762746 | 0.84 | KCNH2 (0.47) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL2763131 | 0.83 | KCNH2 (0.49) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL6793409 | 0.83 | MEN1 (0.47) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL2762846 | 0.78 | MEN1 (0.51) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL1502290 | 0.78 | MEN1 (0.51) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| Methylene Chloride SCHEMBL27848258 | 0.76 | MEN1 (0.47) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL11057658 | 0.75 | MEN1 (0.63) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL3674393 | 0.75 | RAB9A (0.51) | MEN1KMT2ANPC1RAB9ASRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101311165-B | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | AVENTIS PHARMA INC | 2011-05-18 | — | — | CN | disclosed |
| EP-1091938-B1 | ANTIHISTAMINIC PIPERIDINE DERIVATIVES AND INTERMEDIATES FOR THE PREPARATION THEREOF | AVENTISUB II INC (US) | 2010-10-20 | — | — | EP | disclosed |
| CN-100522921-C | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | AVENTIS PHARMA INC (US) | 2009-08-05 | — | — | CN | disclosed |
| CN-101311165-A | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | AVENTIS PHARMA INC (US) | 2008-11-26 | — | — | CN | disclosed |
| CN-1807394-A | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | AVENTIS PHARMA INC (US) | 2006-07-26 | — | — | CN | disclosed |
| CN-1246312-C | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | AVENTIS PHARMA INC (US) | 2006-03-22 | — | — | CN | disclosed |
| US-6930197-B2 | Antihistaminic piperidine derivatives and intermediates for the preparation thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2005-08-16 | — | — | US | disclosed |
| US-6730791-B2 | FOR THERAPY OF ALLERGIES | AVENTIS PHARMACEUTICALS INC. | 2004-05-04 | — | — | US | disclosed |
| US-6700012-B2 | FOR THERAPY OF ALLERGIC DISORDERS | AVENTIS PHARMACEUTICALS INC. | 2004-03-02 | — | — | US | disclosed |
| US-6689898-B2 | FOR THERAPY OF ALLERGIES | AVENTIS PHARMACEUTICALS INC. | 2004-02-10 | — | — | US | disclosed |
| US-6673933-B2 | 1-(3-(4-(1,1-BIS(ALKYOXYCARBONYL)ALKYL)PHENYL)CARBONYLPROPYL), 4-(HYDROXYDIPHENYLMETHYL)PIPERIDINE | AVENTIS PHARMACEUTICAL INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030022919-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2003-01-30 | — | — | US | disclosed |
| US-20020111513-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-08-15 | — | — | US | disclosed |
| US-20020099088-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-07-25 | — | — | US | disclosed |
| US-20020099077-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-07-25 | — | — | US | disclosed |
| US-20020099090-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-07-25 | — | — | US | disclosed |
| US-20020099091-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-07-25 | — | — | US | disclosed |
| CN-1308611-A | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | AVENTIS PHARMA INC (US) | 2001-08-15 | — | — | CN | disclosed |
| EP-1091938-A2 | ANTIHISTAMINIC PIPERIDINE DERIVATIVES AND INTERMEDIATES FOR THE PREPARATION THEREOF | Aventis Pharmaceuticals Inc. (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001671-A2 | ANTIHISTAMINIC PIPERIDINE DERIVATIVES AND INTERMEDIATES FOR THE PREPARATION THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099088-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH2, HRH1, HRH4 | MEN1 2411/4885KMT2A 701/4885NPC1 1460/4885 |
| US-20020111513-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | MEN1 1433/4885KMT2A 645/4885NPC1 895/4885 |
| US-20020099077-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | MEN1 1385/4885KMT2A 777/4885NPC1 708/4885 |
| US-20030022919-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | MEN1 1900/4885KMT2A 683/4885NPC1 860/4885 |
| US-20020099091-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | MEN1 1535/4885KMT2A 1089/4885NPC1 976/4885 |
| US-20020099090-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | MEN1 1481/4885KMT2A 728/4885NPC1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.